Latest from ISC 2017
Efficacy of triple antiplatelet therapy compared with current guideline-based therapy for the prevention of recurrent stroke was evaluated in the TARDIS trial.
More patients receiving VNS experienced enhanced arm movement over a 90-day period.
Restarting anticoagulation after both nonlobar and lobar ICH was associated with decreased mortality.
Men were more likely than women to be treated with IV tPA within 30 minutes of arrival at a hospital.
As more patients survive ICH, emphasis is slowly shifting from survival to improving ICH-related morbidity and optimization of functional recovery.
The results provide good evidence for the use of contact aspiration in ischemic stroke.
Optimal antiplatelet treatment has yet to be determined for stroke survivors with prior intracerebral hemorrhage.
The co-presentation of headache at stroke onset in children may provide clues to underlying pathophysiologic mechanisms.
Psychological distress may cause changes within cells that trigger inflammation and oxidative stress, both of which are believed to increase stroke risk.
Delays related to the determination of treatment eligibility increased door-to-needle times by more than 30 minutes compared with patients with no delays.
Sign Up for Free e-newsletters
Check out what's trending
Neurology Advisor Articles
- New Sleep Apnea Clinical Practice Guidelines
- International League Against Epilepsy Updates Epilepsy Classification System
- In Refractory Status Epilepticus, Lacosamide May Be a Good Option
- Patent Foramen Ovale Closure Reduces Stroke Risk in Patients With Inherited Thrombophilias
- The Handoff: Your Week in Neurology News - 3/23/17
- Q&A: Strategies for Transitioning Pediatric Patients to Adult Care
- Epilepsy Risk May Increase After Incident Depression
- Alzheimer's Caregiver Coping Program Does Not Increase Health Care Costs
- Valproate for Epilepsy Poses Greater Risk for Major Congenital Malformations
- VTE Recurrence Decreased With Rivaroxaban